Get started
Work

Points to consider when doing a trial primarily involving the heart

Year: 2017
Type: review
Abstract: Cardiac involvement contributes to the severity of SSc and should carefully be investigated and managed in SSc patients. Although it is commonly sub-clinical, once symptomatic it has a poor prognosis. Several complementary tools (circulating biomarkers, electrocardiography, echocardiography, scintigraphy or MRI) allow the assessment of all the various cardiac structures (endocardium, myocardium and pericardium) and heart function. Treatment remains empirical but cardiac trials in SSc can add data to the treatment of this complication.
Source: Rheumatology
DOI: 10.1093/rheumatology/kex198
Authors: Yannick Allanore, Oliver Distler, Ulrich A. Walker, Dinesh Khanna, Daniel E. Furst, Christophe Meune
Institutions: Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris Descartes, University Hospital Zurich, University of Basel, University of Michigan, University of California, Los Angeles
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Pfizer, National Institutes of Health, Genentech, National Institute of Arthritis and Musculoskeletal and Skin Diseases
OpenAlex ID: W2762093674
FWCI: 0.263
Cites: 33
Cited by: 7
Related to: 10